Alkermes plc Dossier
Qualitative Analysis
Business overview
Alkermes plc (Nasdaq: ALKS) is a fully integrated, global biopharmaceutical company specializing in the research, development, and commercialization of innovative medicines in the field of neuroscience. The company's commercial portfolio includes proprietary products for central nervous system (CNS) disorders, such as Lybalvi (olanzapine and samidorphan) for schizophrenia and bipolar I disorder, Aristada (aripiprazole lauroxil) for schizophrenia, and Vivitrol (naltrexone for extended-release injectable suspension) for alcohol and opioid dependence. In February 2026, Alkermes completed the strategic acquisition of Avadel Pharmaceuticals plc, integrating LUMRYZ (sodium oxybate extended-release oral suspension) into its sleep medicine portfolio.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Accelerating entry into the commercial sleep medicine market through the integration of Avadel Pharmaceuticals and its FDA-approved product LUMRYZ, establishing a commercial infrastructure in rare sleep disorders.
Expected impact: Diversifies the revenue base away from legacy psychiatry and addiction products, adding an immediate commercial growth driver with projected 2026 LUMRYZ sales of $315 million to $335 million.
Advancing alixorexton (formerly ALKS 2680), an oral selective orexin 2 receptor agonist, through clinical development for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia.
Expected impact: Establishes a potential best-in-class franchise in central disorders of hypersomnolence, leveraging the commercial sleep medicine infrastructure established via the Avadel acquisition.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire LUMRYZ, an FDA-approved once-nightly sodium oxybate formulation for narcolepsy, accelerating Alkermes' entry into the sleep medicine market and establishing a specialized commercial rare disease organization.
Financial impact: Expected to be accretive to earnings in 2026. Financed using $775 million of cash and $1.525 billion in term loans due in 2031. Contributed $39.5 million in net sales during partial Q1 2026, with full-year 2026 LUMRYZ sales projected at $315 million to $335 million.